An observational study in Intestine Disease, sponsored by University of Erlangen-Nürnberg Medical School. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by University of Erlangen-Nürnberg Medical School · Observational
The study evaluates the effect of nutrient antigens or therapeutic agents on human small intestinal organoids.
Small intestinal biopsies will be taken to establish human intestinal organoids in vitro. The organoids will be propagated and various antigens will be checked for their effects on proliferation, production of inflammatory components or signal cascade.
-Patients with patients with Food intolerances, Food allergy, intestinal disorders, glutensensitivity, healthy controls who underwent a gastroduodenoscopy or coloscopy for therapeutical intervention or screening
Exclusion Criteria:
healthy controls
patients with Food intolerances or Food allergy
patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
Determination of proliferation, apoptosis, histology, and cytokine Expression before and after Antigen provocation of organoids with gluten peptides, nutritional Antigens, Glucagon like peptide antagonist, or Tumor nekrose factor antagonists
Determination of effects on organoids after antigen Stimulation with ELISA, histochemistry, RNA or proteome analysis
Time frame: baseline vs 24h vs 48h vs 72h
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School